🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to researchers.

A Global Challenge

Cases of gonorrhoea are increasing globally, with figures suggesting over 82 million new cases per year. Particularly high rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the face of rising global incidence, the spread of superbugs and the highly restricted therapeutic options at this time.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Therapies Gain Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Scientists believe that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This authorization signifies a significant shift in the management of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Data and Global Access

According to results detailed in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which involves a dual-drug approach. The study involved nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the authority to register and commercialise the drug in many developing nations.

Doctors directly involved have voiced optimism. The availability of a easy-to-administer therapy like this is described as a "critical tool" for public health efforts. This is deemed vital to lessen the impact of the infection for patients and to prevent the spread of extremely resistant gonorrhoea globally.